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ABSTRACT 
 
Purpose: Until now, real-time image guided adaptive radiation therapy (IGART) has been the domain 
of dedicated cancer radiotherapy systems. The purpose of this study was to clinically implement and 
investigate real-time IGART using a standard linear accelerator.  
 
Materials/Methods: We developed and implemented two real-time technologies for standard linear 
accelerators: (1) Kilovoltage Intrafraction Monitoring (KIM) that finds the target and (2) multileaf 
collimator (MLC) tracking that aligns the radiation beam to the target.  Eight prostate SABR patients 
were treated with this real-time IGART technology. The feasibility, geometric accuracy and the 
dosimetric fidelity were measured. 
 
Results: Thirty-nine out of forty fractions with real-time IGART were successful (95% confidence 
interval 87%-100%). The geometric accuracy of the KIM system was -0.1±0.4, 0.2±0.2 and -0.1±0.6 
mm in the LR, SI and AP directions, respectively.  The dose reconstruction showed that real-time 
IGART more closely reproduced the planned dose than that without IGART. For the largest motion 
fraction, with real-time IGART 100% of the CTV received the prescribed dose; without real-time 
IGART only 95% of the CTV would have received the prescribed dose.  
 
Conclusion: The clinical implementation of real-time image-guided adaptive radiotherapy on a 
standard linear accelerator using KIM and MLC tracking is feasible. This achievement paves the way 
for real-time IGART to be a mainstream treatment option. 
 
  
*Annotated Revised Mansucript
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INTRODUCTION 
Until now, real-time image-guided adaptive radiation therapy (IGART) has been the domain of 
dedicated and often expensive cancer radiotherapy systems such as the CyberKnife Synchrony
1
 and 
Mitsubishi/BrainLab Vero.
2
 The purpose of this study was to clinically implement and investigate 
real-time IGART using a standard linear accelerator. 
 
We developed two real-time image guidance technologies for standard linear accelerators: 
(1) Kilovoltage Intrafraction Monitoring (KIM) that finds the target position in real-time during 
radiotherapy and (2) multileaf collimator (MLC) tracking that aligns the radiation beam to the moving 
target.   
 
KIM is an image-based real-time localization method first clinically implemented in 2014
3
 that has 
been used in over 1200 treatment fractions for prostate cancer in five different cancer centers.  Prior to 
the current study, all treatments with KIM have been gated. When the observed target motion 
exceeded a threshold the treatment was interrupted and a manual couch shift was performed to realign 
the target with the radiation beam. The motion threshold is typically ≥3 mm displacement for 
5 seconds for conventional fractionation, and ≥2mm of motion for 5 seconds for stereotactic ablative 
body radiotherapy (SABR).  
 
MLC tracking is a real-time adaptive radiotherapy method first clinically implemented in 2013
4
 that 
has been used in over 800 treatment fractions for prostate and lung cancer. Prior to the current study, 
the clinical implementation of MLC tracking had been restricted to a research version of the Calypso
5
 
electromagnetic transponder-guided localization method. Calypso is an add-on to the standard 
equipped linear accelerator, and requires additional hardware. KIM is a software-based real-time 
system that uses the hardware of a standard equipped linear accelerator.  
 
When put together, KIM and MLC tracking enable real-time IGART using a standard linear 
accelerator without any additional hardware. The purpose of this study was to clinically implement 
and investigate real-time IGART using KIM and MLC tracking. 
 
METHODS 
Clinical details 
Eight prostate SABR patients enrolled on the TROG 15.01 SPARK (NCT02397317) clinical trial 
were treated. SPARK = Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage 
Intrafraction Monitoring. The CTV margins were 5 mm isotropically except 3 mm posteriorly. The 
prescribed dose was 36.25 Gy to 95% of the PTV in five 7.25 Gy fractions. Study protocol details are 
given in reference 6 and https://clinicaltrials.gov/ct2/show/NCT02397317.   
 
Clinical process 
Patients were implanted with three gold fiducials markers and hydrogel one week prior to simulation. 
Simulation images were acquired on a Philips BigBore CT scanner with 1.5mm slices. Fiducial 
markers were defined as high definition structures and the centroid position of the three fiducials was 
defined to be the treatment isocenter. Eligibility criteria included a patient lateral dimension of <40cm 
at level of isocenter and correct positioning of fiducials (three markers intact and no markers at the 
same superior-inferior level). A dual arc volumetric modulated arc treatment was planned using 
Eclipse v13.6 (Varian Medical Systems, Palo Alto) to satisfy the SPARK trial dose-volume 
constraints. After the treatment plan optimization was complete, the field size was manually enlarged 
by 1.6cm (0.8cm on each side) without changing the MLC to allow MLC tracking without causing a 
beam hold if the target moves below the jaw. The change in jaw position required the dose to be 
recalculated and the plan was renormalized, and the dose-volume constraints were reconfirmed 
against SPARK trial requirements.  
 
Patients were treated on a Varian Trilogy linac with Millennium MLC. Positioning was verified with 
CBCT to align fiducials and cross-checked with CTV and PTV structure overlay. Framegrabber 
hardware cables and acquisition software (Varian iTools) were used to acquire kV and MV images 
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during treatment. The images were streamed to a research computer on which the KIM and MLC 
tracking programs were installed. The research computer was integrated into the linac intranet to 
enable MLC positions and beam holds to be sent from the MLC tracking software to the linac. The 
KIM software was activated following patient alignment and preceding treatment delivery, requiring 
the patient’s implanted marker positions determined from the treatment plan to be loaded and 
acquisition of kV fluoroscopy during a 120° imaging only arc to populate the KIM probability density 
function.
3
 The MLC tracking software was activated with the MLC positions as a function of gantry 
angle and monitor unit obtained by reading the DICOM RT plan. Treatment was delivered with kV 
fluoroscopy (125kVp, 80mA, 13 ms, 6×6cm
2
, 10Hz). The estimated additional kV dose from the KIM 
procedure is 0.4Gy.
7
 A gating threshold of 1cm was applied. Following treatment a second CBCT was 
acquired according to the SPARK protocol.  
 
Quality assurance  
For the TROG 15.01 SPARK trial, in addition to routine departmental procedures, the contours and 
dose distributions for each patient’s plan were independently reviewed. The KIM and MLC tracking 
quality assurance processes were based on previous publications.
8,9
  System tests (repeated monthly) 
included coordinate system check, dynamic tracking accuracy, treatment interruption, latency 
measurement, dosimetric accuracy for standard delivery and kV panel offset correction with gantry 
angle. We also deployed software-based, patient-specific geometric and patient-specific dosimetric 
controls as a comprehensive quality assurance program applied pre-treatment, during treatment and 
post-treatment. The pre-treatment quality assurance included: 
 Planning task checklist. 
 Monitor Unit check with IMSURE (Standard Imaging) with a tolerance of ±3%. 
 Delivery of the plan using KIM and MLC tracking to a motion phantom programmed with 
typical prostate motions to determine deliverability (i.e. no beam holds) and geometric 
accuracy (tolerance as mean value and root mean square error <1mm) 
 Measurement of delivered dose with MLC tracking applied to a programmable motion 
phantom holding an anthropomorphic phantom containing GAF film in the coronal plane 
attached to HexaMotion (ScandiDos, Uppsala, Sweden). Applied tolerance of 98% of points 
within 2%/2mm gamma comparing measurement with motion and tracking against 
measurement without motion. A further comparison was made between measured and 
planned dose distribution. 
 
The during-treatment quality assurance included: 
 Visual inspection of segmentation and that the reported motion corresponded to segmented 
positions relative to planned positions 
 Software controlled measures (inside KIM software) leading to beam hold interlocks on the 
linear accelerator, including: loss of communication between KIM, MLC tracking or MLC 
controller; detection of motion outside tracking zone; reduction of correlation below a 
threshold (to detect migration, or segmentation error); change in inter-marker distances (to 
detect deformation, segmentation error, or 2D→3D conversion error); acceleration of 
centroid over a threshold value (to detect 2D→3D conversion error) 
 
The post-treatment quality assurance included: 
 kV/MV triangulation as ground truth and comparison with KIM real-time trajectory to assure 
accuracy of prostate motion trajectory feeding MLC tracking 
 reconstruction of delivered dose utilizing prostate motion trajectory, MLC logfiles and 
original treatment plan as described elsewhere
10,11
  
 
Measurements 
Three factors affecting the patient’s treatment were analyzed: feasibility, geometric accuracy of the 
KIM system, and dosimetric fidelity of the integrated KIM-MLC real-time IGART system.  
1. Feasibility was measured using maximum likelihood estimates (Matlab’s binofit function) 
assuming a binomial distribution of a successful or unsuccessful treatment. A successful 
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treatment was defined as the entire treatment fraction was delivered with KIM-guided MLC 
tracking.  
2. The geometric accuracy of the KIM system was measured by comparing the KIM-measured 
motion to the motion measured using post-treatment kV/MV triangulation. 
3. The dosimetric fidelity of the integrated KIM-MLC IGART system was measured using a 
previously published dose reconstruction technique.
10
 The dose reconstruction method 
combines the original treatment plan, the KIM-measured motion files and the treatment log 
files that have the MLC leaf positions, gantry angles, couch shifts and monitor units 
delivered, to estimate the dose delivered in the presence of motion, both with and without 
IGART. A limitation of the dose reconstruction method is that the dose reconstruction is 
performed on the initial planning CT scan to avoid the uncertainties introduced by both dose 
calculation on CBCT scans and deformably registering CBCT to CT.  
The study design is shown schematically in Figure 1. 
 
 
Figure 1.  A schematic of the integration of real-time IGART on a standard linac. The two 
experimental technologies to find the target and hit the target, respectively KIM and MLC tracking, 
are integrated to enable real-time IGART.  
 
RESULTS 
Feasibility 
Thirty-nine out of forty treatment fractions with real-time IGART using the KIM and MLC tracking 
technologies were successful.  This yields a maximum likelihood probability estimate for feasibility 
of 97.5%, with 95% confidence intervals of (87%, 100%). One of the 40 fractions (patient 2 fraction 
1) only used KIM with gating and not MLC tracking. For patient safety reasons, MLC tracking was 
not attempted in this fraction as quality assurance processes had not been completed following a 
software revision. A video of the KIM and MLC tracking software interfaces at the treatment console 
is shown in supplementary material video.   
 
The time for the real-time IGART SABR treatment fractions from the end of the cone beam alignment 
to the completion of treatment delivery ranged from 5.6 to 15 minutes, with a mean of 7.7 and a 
median of 7.0 minutes.    
 
Geometric accuracy of the KIM system 
Overall, prostate motion greater than 3, 5 and 7 mm was observed in 38%, 9.0% and 6.2% of the 40 
treatment fractions respectively.  The mean±standard deviation of the geometric accuracy of the KIM 
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system over all 40 fractions was -0.1±0.4, 0.2±0.2 and -0.1±0.6 mm in the LR, SI and AP directions, 
respectively.   
 
Dosimetric fidelity of the integrated KIM-MLC IGART system 
The dose reconstruction results showed that real-time IGART reproduced the planned dose in the 
presence of intrafraction motion. The CTV and PTV doses were consistently higher with IGART than 
without IGART. The rectal and bladder doses were consistently closer to that planned for each 
fraction with IGART than without IGART. Dose volume histograms of the doses summed over each 
fraction are shown in Figure 2.  
 
 
Figure 2.  Dose volume histograms (DVHs) for planned, delivered with real-time IGART, and 
estimated without real-time IGART (no motion correction) for the first four SABR patients treated 
with KIM and MLC tracking. The plan sum DVHs represent the dose summed over each of the five 
fractions.  
 
Individual fraction analysis 
For prostate cancer SABR, there can often be little target motion. The cases of most interest from a 
real-time tracking perspective are those at the tails of the distribution where motion management is 
more critical.  We focused the individual analysis on the fraction (patient 3, fraction 5) with the 
largest observed target motion (most time spent ≥3 mm from isocenter). For this fraction, where over 
8 mm of target motion was observed from the start to the end of treatment, the target motion, isodose 
distributions and dose volume histograms are shown in Figure 3, Figure 4 and Figure 5 respectively. 
The 5 mm displacement at the start of treatment occurred due to prostate motion that occurred after 
the cone beam CT acquisition and before the start of treatment.  
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Figure 3.  The KIM-measured target motion for the treatment fraction with the largest measured 
motion (patient 3 fraction 5) for the dual arc SBRT VMAT treatment. The gap in data is the time 
between the two treatment arcs to allow for collimator rotation. The kV beam was turned off to reduce 
imaging dose. Overlaid are the post-treatment measured kV/MV triangulated positions.  
 
 
Figure 4.  Isodose distributions for planned (left), delivered with real-time IGART (middle), and 
estimated without real-time IGART (right) for the fraction with the motion shown in Figure 3. The 
isodose range is from the PTV 95% (prescribed dose) to 110%.   
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Figure 5.  Dose-volume histograms of the planned (continuous line), delivered with real-time IGART 
(dashed line), and estimated without real-time IGART (dotted line) for the fraction shown in Figure 3 
and Figure 4.  
 
For the largest motion fraction (Figure 3), the mean±one standard deviation of the geometric accuracy 
of the KIM system was -0.3±0.6, 0.4±0.2 and -0.1±0.6 mm in the LR, SI and AP directions, 
respectively, indicating that the geometric accuracy was not affected by the motion magnitude. 
Without KIM, the geometric accuracy of this treatment would have been -2.3±0.8, 0.1±1.9 and 
0.9±2.0 mm in the LR, SI and AP directions respectively. Analyzing the dose volume histogram for 
the largest motion fraction (Figure 5), with real-time IGART 100% of the CTV received the 
prescribed dose; without real-time IGART only 95% of the CTV would have received the prescribed 
dose.  
 
DISCUSSION 
It is acknowledged that motion management is more important for SABR treatments given the fewer 
number of fractions.
12
 In this study, a standard linear accelerator was used to enable real-time IGART 
for eight prostate cancer SABR patients by utilizing two emerging technologies, KIM and MLC 
tracking. To put this achievement in context using Australia as an example, over 95% of the cancer 
radiotherapy systems are standard C-arm linacs. KIM and MLC tracking are software tools that enable 
these standard linacs to be used as real-time image-guided adaptive radiotherapy systems. Therefore, 
there is potential for these technologies to be broadly implemented for real-time adaptive 
radiotherapy.   
 
Intratreatment 2D guidance on Elekta and Varian systems has been implemented using the in-house 
SeedTracker system
13
 and the vendor-supplied Triggered Imaging package.
14
  These 2D imaging 
approaches have been clinically implemented for gating and have resulted in CTV-PTV margin 
reduction.
14
 However the 2D information lacks the motion component perpendicular to the treatment 
beam in one direction and limits the ability to perform more advanced functions that are enabled by 
3D motion monitoring, such as MLC tracking, couch tracking or dose reconstruction. Common to all 
of these methods is the additional kV imaging dose that should be kept to a minimum whilst 
maintaining the utility of real-time guidance.   
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For the task of real-time guidance, in addition to KIM, other marker-based kilovoltage imaging 
approaches to obtain the 3D target position from gantry-mounted 2D images have been published, e.g. 
the the arbitrary-shape PDF method.
15
 KIM is the only approach in this class that has been clinically 
implemented.  However, different formalisms to solve the 2D→3D problem would presumably offer 
similar performance.   
 
Only adaptation to 3D translational motion was implemented in this study. KIM measures the 
translation and rotation (6 degree-of-freedom motion) of the target,
16
 and MLC tracking has been 
experimentally demonstrated to correct for in-plane rotation
17
 and potentially can correct for out-of-
plane rotation if dose accumulation and optimization is performed in the patient anatomy. Explicitly 
adapting for rotation is part of future KIM-MLC tracking integration research.  
 
For prostate cancer radiotherapy, gating and MLC tracking are probably equivalent in accuracy and 
the dosimetric implcations.
18
 MLC tracking is slightly more efficient as it enables treatment to start 
immediately after correction and obviates the need for corrections during treatment.  In the SPARK 
trial, for the KIM-guided gating treatments (non-MLC tracking), there is on average one intra-
treatment gating event per fraction using a threshold of motion of the target moving more than 2mm 
from isocenter for more than 5 seconds. MLC tracking has a smoother workflow, higher degree of 
automation and less operator involvement than gating. Although large motion is relatively rare for 
prostate SABR, real-time IGART provides a safety net that ensures accurate dose delivery even when 
the large motion occurs.  Real-time IGART will likely be more beneficial for future-planned 
applications of KIM-MLC tracking to thoracic and abdominal sites where motion can be large and 
variable, enabling accurate and efficient treatment delivery.  
 
A similar goal of real-time IGART on a standard linear accelerator couch could be achieved by 
implementing KIM with couch tracking.
19-21
 Couch tracking is attractive for prostate motion 
correction as the motion is generally slow and small, and also very intuitive – the KIM motion signal 
should be close to (0,0,0) at all times as the couch would shift the patient (and target) in the opposite 
direction to the KIM-measured motion.  From a future perspective of integrating KIM with couch 
tracking for rotation, the couch is limited to correcting only small angles in the roll and pitch 
directions, and yaw corrections may also introduce a collision risk. Rotational correction with the 
couch will alter the beam path through the patient. Couch tracking will also be limited for advanced 
treatments where deformation correction may be needed, for example when treating locally advanced 
prostate cancer and the prostate moves with respect to the nodes,
22-24
 requiring the beam shape to 
change.   
 
CONCLUSION 
The clinical implementation of real-time IGART using a standard linear accelerator using KIM and 
MLC tracking is feasible. This achievement paves the way for this technology to be tested more 
broadly, enabling more accurate radiotherapy on widely available linear accelerators, and ushering in 
the era of real-time radiotherapy as a mainstream treatment option. 
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